Clinical Trial Update: Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients [Phase 1, Phase 2]

View source ↗

Summary

This document reports a completed Phase 1/2 clinical trial evaluating a Toll-like receptor ligand–matured dendritic cell vaccine in patients with melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• TLR ligand-matured dendritic cell vaccine

Snippet

Sponsor: Radboud University Medical Center | Conditions: Melanoma | Phase 1, Phase 2 | Status: COMPLETED